中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

96 records (took 0.017 seconds)

    SPRAYABLE POLYMERS AS ADHESION BARRIERS
    31.
    发明申请
    SPRAYABLE POLYMERS AS ADHESION BARRIERS 审中-公开
    可喷涂聚合物作为粘合层

    公开(公告)号：WO2011031457A2

    公开(公告)日：2011-03-17

    申请号：PCT/US2010/046529

    申请日：2010-08-24

    Applicant: ARA MEDICAL,LLC ,  EATON, Donald J. ,  HUANG, Bin ,  SAVITT, Michael A.

    Inventor： EATON, Donald J. ,  HUANG, Bin ,  SAVITT, Michael A.

    IPC: A61L15/22 ,  A61L15/62 ,  A61L15/60 ,  A61L15/44 ,  A61F13/00 ,  A61M35/00

    CPC classification number: A61K9/0014 ,  A61K9/12 ,  A61K31/765 ,  A61K47/32 ,  A61K47/36 ,  A61L26/0076 ,  C08L5/08 ,  C08L23/0869 ,  C08L29/04 ,  C08L2201/06

    Abstract: A formulation for generating an adhesion barrier that includes a plurality of particles or a dry powder that is made of a polymer combination of at least one biodegradable polymer and at least one water soluble polymer is disclosed. Methods of making and delivering the formulation are further disclosed. The formulation of particles is deposited on a surface of internal body tissue and the deposited formulation absorbs moisture from the tissue and forms a film over the surface. The film acts as an adhesion barrier by reducing or preventing adhesion of the surface to other body tissue.

    Abstract translation: 公开了一种用于产生粘附屏障的制剂，所述粘附屏障包括由至少一种生物可降解聚合物和至少一种水溶性聚合物的聚合物组合制成的多个颗粒或干粉。 进一步公开了制备和递送制剂的方法。 颗粒的制剂沉积在体内组织的表面上，并且沉积的制剂从组织吸收水分并在表面上形成薄膜。 该膜通过减少或防止表面与其他身体组织的粘附而用作粘附屏障。

    SETTING LASER POWER FOR LASER MACHINING STENTS FROM POLYMER TUBING
    32.
    发明申请
    SETTING LASER POWER FOR LASER MACHINING STENTS FROM POLYMER TUBING 审中-公开
    从聚合物管设置激光加工机的激光功率

    公开(公告)号：WO2011029044A1

    公开(公告)日：2011-03-10

    申请号：PCT/US2010/047880

    申请日：2010-09-03

    Applicant: ABBOTT CARDIOVASCULAR SYSTEMS INC. ,  JOW, Kevin

    Inventor： JOW, Kevin

    IPC: B23K26/00 ,  A61F2/82

    CPC classification number: A61F2/91 ,  A61F2240/001 ,  B23K26/0624

    Abstract: Laser machining polymer tubing sections to form stents such that the power of the laser machining is adjusted for each tubing section to obtain repeatable strut widths for stents formed from different tubing sections is disclosed. A threshold power for laser machining each section is determined and the power used for machining each section is based on the threshold power.

    Abstract translation: 激光加工聚合物管道部分以形成支架，从而针对每个管道部分调整激光加工的功率以获得由不同管道部分形成的支架的可重复的支柱宽度。 确定激光加工每个部分的阈值功率，并且用于加工每个部分的功率基于阈值功率。

    DEUTERATED WATER AND RIBOFLAVIN SOLUTION FOR EXTENDING SINGLET OXYGEN LIFETIMES IN TREATMENT OF OCULAR TISSUE AND METHOD FOR USE
    33.
    发明申请
    DEUTERATED WATER AND RIBOFLAVIN SOLUTION FOR EXTENDING SINGLET OXYGEN LIFETIMES IN TREATMENT OF OCULAR TISSUE AND METHOD FOR USE 审中-公开
    电生理盐水和紫杉烷溶液延长单眼氧生命治疗眼组织的方法及使用方法

    公开(公告)号：WO2011019940A2

    公开(公告)日：2011-02-17

    申请号：PCT/US2010/045356

    申请日：2010-08-12

    Applicant: SEROS MEDICAL, LLC ,  HEREKAR, Satish V.

    Inventor： HEREKAR, Satish V.

    IPC: A61K47/38 ,  A61K47/42 ,  A61K31/14 ,  A61K31/205 ,  A61K9/08 ,  A61P27/02

    CPC classification number: A61K31/14 ,  A61K9/0048 ,  A61K31/205 ,  A61K33/00 ,  A61K2300/00

    Abstract: A solution of deuterated water containing a riboflavin-based photosensitizer is provided in order to extend lifetimes of UVA/Rf photo-generated intra-stromal singlet oxygen, in combination with UVA delivery profiles of pulsing, fractionation, and optionally auxiliary stromal/Rf hyper-oxygenation in order to accelerate protein cross-linking density rates in ocular tissue. A 100% deuterated water solution with 0.1% riboflavin in solution increases singlet oxygen lifetimes by at least an order of magnitude without inducing endothelial cell apoptosis, thereby also permitting use of some combination of lower percentages of deuterated water, lower concentrations of riboflavin or lower dosages of UVA on intact (un-debrided) epithelium for equivalent cross-link densities compared to current acceptable corneal cross-linking procedures. Lower concentrations of deuterated water with regular water, for example, yields shorter singlet oxygen lifetimes in approximately linear proportion to concentration, which are considered acceptable in therapies known or being developed in the art of corneal cross-linking.

    Abstract translation: 提供包含基于核黄素的光敏剂的氘化水溶液以延长UVA / Rf光生基质内单线态氧的寿命并结合脉冲，分馏等UVA递送曲线。 和任选的辅助基质/ Rf过氧化，以加速眼组织中的蛋白质交联密度速率。 溶液中含有0.1％核黄素的100％氘代水溶液使单线态氧寿命增加至少一个数量级，而不诱导内皮细胞凋亡，从而也允许使用较低百分比的氘代水，较低浓度的核黄素或较低剂量 的UVA对完整（未去除）上皮的等效交联密度与当前可接受的角膜交联程序相比。 例如，较低浓度的含有常规水的氘化水产生较短的单线态氧寿命，与浓度成近似线性比例，这在角膜交联领域已知或正在开发的治疗中被认为是可接受的。

    POLYESTER IMPLANTABLE MEDICAL DEVICE WITH CONTROLLED IN VIVO BIODEGRADABILITY
    37.
    发明申请
    POLYESTER IMPLANTABLE MEDICAL DEVICE WITH CONTROLLED IN VIVO BIODEGRADABILITY 审中-公开
    具有生物可降解性控制的聚酯可植入医疗器械

    公开(公告)号：WO2010002621A2

    公开(公告)日：2010-01-07

    申请号：PCT/US2009/048164

    申请日：2009-06-22

    Applicant: ABBOTT CARDIOVASCULAR SYSTEMS INC. ,  WANG, Yunbing

    Inventor： WANG, Yunbing

    IPC: A61L31/04 ,  A61L31/14

    CPC classification number: A61L31/041 ,  A61K9/0024 ,  A61K9/1647 ,  A61L27/26 ,  A61L31/148 ,  C08L67/04

    Abstract: This invention relates to blends of high, optionally medium, and low molecular weight polyesters where at least the low molecular weight polyester is substituted with an acidic moiety, the biodegradation of the blends being controllable by selection of the mean molecular weigh of each fraction, the quantity of each fraction in the blend and the amount and pKa of the acidic moiety(ies).

    Abstract translation: 本发明涉及高，任选中等和低分子量聚酯的共混物，其中至少低分子量聚酯被酸性部分取代，共混物的生物降解可通过选择各部分的平均分子量来控制， 共混物中每个级分的量和酸性部分的量和pKa。

Patent Agency Ranking